Colin John Meyer, Chief Research Officer at REATA PHARMACEUTICALS INC (RETA), sold 25,000 shares at $175.00 ($4.4M) on 2020-11-09, disclosed to the SEC on 2020-11-10.
Open-market sale of $4.4M RETA by Chief Research Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| RETA | SELL | 2023-03-08 | $105K | — | Filing → |
| RETA | SELL | 2023-03-06 | $16.3M | — | Filing → |
| RETA | SELL | 2021-06-16 | $16.4M | — | Filing → |